Release Date: April 23, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you clarify if there was an option to exit the GET transaction at any point? A: Per Brilioth, Managing Director, explained that they are bound by a Sale and Purchase Agreement (SPA) which does not allow for an exit unless the transaction fails to close within the agreed timeframe. This timeframe aligns with the ongoing discussions with the antitrust authorities.
Q: Are you pushing for the GET transaction to go through despite its valuation? A: Per Brilioth stated that while they are committed to the transaction, they are also comfortable with retaining GET if the deal does not close. The decision to sell was made to reduce debt, and they believe it was the right move at the time.
Q: What is the path to value crystallization for the portfolio in 2025? A: Per Brilioth mentioned that they are working on exiting smaller positions to generate liquidity. However, they do not expect any major IPOs in 2025, with potential IPOs more likely in 2026.
Q: Are there regulatory risks for Newman related to GLP-1 prescriptions? A: Dennis Mohammed, Investment Manager, noted that while there are ongoing studies, the current outlook is positive, especially in the UK. There is a risk of regulatory changes, but the situation is currently favorable.
Q: In the event the GET transaction does not close, what distribution can be expected? A: Per Brilioth indicated that a significant portion of GET's cash position could be distributed quickly, potentially amounting to 15-20% of the exit price. Further dividends could be expected from a more efficient balance sheet.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.